Tran Le was pursuing her engineering studies at Stanford University when she sought to join a clinical trial for her chronic illness. Despite identifying several suitable trials, she found the registration process overwhelming, entailing extensive email exchanges with clinical sites and filling out lengthy forms that stretched up to 20 pages.
The cumbersome nature of this paperwork inspired Le to leverage generative AI to streamline the trial enrolment process, reducing it from weeks to mere minutes. Earlier this year, she collaborated with Sohit Gatiganti, a fellow engineer at Stanford Medicine, to establish Grove AI.
While many patients receive referrals to clinical trials from their doctors, numerous individuals also search independently for suitable trials through platforms like clinicaltrials.gov. These registries are beneficial for identifying relevant studies, but contacting trial administrators can often be a laborious and time-consuming process. In the healthcare sector, challenges such as understaffing, bureaucratic red tape, and outdated systems frequently impede progress.
Le and Gatiganti (illustrated above) assert that Grove AI’s agent, Grace, can alleviate the enrolment bottleneck by reaching out to patients as soon as they express interest in a trial.
Grace employs a voice-activated AI agent to pose pre-screening questions, assessing a patient’s eligibility for a trial. Should a patient qualify, Grace can organise a first visit to the clinical site for trial managers to make a final decision.
Since its inception eight months ago, Grove AI claims to have engaged with 250,000 patients, arranged 7,000 in-person appointments, and secured two customers with multi-year contracts.
While Grove AI addresses a straightforward issue, Le and Gatiganti emphasise that no other company has harnessed generative AI to accelerate patient enrolment in trials. “Numerous players in this field are approaching us and expressing great interest in partnerships,” remarked Le.
Investors also recognise potential value in minimising the bureaucratic challenges tied to clinical trial enrolment.
On Wednesday, Grove AI announced that it had successfully raised $5.2 million in seed funding, spearheaded by the venture firm A*, with contributions from Afore Capital, LifeX Ventures, and Pear VC.
“The target market may not be the largest at present, but I believe it holds significant growth potential,” stated Gautam Gupta, co-founder and general partner at A*. He noted that his firm is confident advancements in AI and computational biology will spur a surge in drug research and clinical trials, positioning Grove as a major beneficiary.
Gupta acknowledged that while the technology driving Grove AI isn’t exceptionally complex, its demand from numerous organisations, many of which have historically been slow to adopt new innovations, excites him about the company’s prospects.
Aside from finding Grove AI’s voice agent intriguing, Gupta sees immense opportunity in the startup’s initiatives to gather and organise patient data into a relationship management tool.
Currently, most clinical sites rely on spreadsheets to track patient interactions; however, Grove is utilising its AI to develop a product that could eventually streamline the management of patient records.
“I cannot quantify that opportunity at this moment, but I am confident it establishes a substantial competitive advantage and will create incremental monetisation opportunities over time,” he noted.
